June 12, 2012
2 min read
Save

Study found no consensus for tests used to diagnose CAP

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Diagnosis and treatment of community-acquired pneumonia varies widely across children’s hospitals, according to recently published study results.

Perspective from John S. Bradley, MD

Thomas V. Brogan, MD, of the division of critical care at Seattle Children’s Hospital, and colleagues evaluated the differences in the use of health care resources in 21,213 patients aged 1 to 18 years with community-acquired pneumonia (CAP) between July 2005 and June 2010. The team examined data from 29 children’s hospitals submitted to the Pediatric Hospital Information System. The researchers ranked care based on eight diagnostic tests and used length of hospital stay, revisit to the ED or readmission to the hospital within 2 weeks of discharge as primary outcomes.

Brogan and colleagues reported a “wide variety” of lab testing and antibiotic use, with cephalosporins being the most commonly prescribed medicine. There was also a variety in length of hospital stay. The researchers said a link between increased diagnostic testing and a longer length of hospital stay was noted and requires further study.

The overall median length of stay was 2 days. Brogan and colleagues also reported that an early discharge did not increase the chance of readmission within 2 weeks.

“The absence of established guidelines during the study years may have contributed to this wide variability in testing, suggesting an important target for influencing both the efficiency and quality of pediatric health care,” the researchers wrote. “Guidelines of care that promote certain laboratory studies may need to be evaluated in light of these findings.”

Disclosure: Dr. Brogan reports no relevant financial disclosures.